stoxline Quote Chart Rank Option Currency Glossary
  
ProPhase Labs, Inc. (PRPH)
0.35  0.017 (5.23%)    06-17 16:00
Open: 0.384
High: 0.4961
Volume: 64,353,374
  
Pre. Close: 0.3326
Low: 0.342
Market Cap: 15(M)
Technical analysis
2025-06-17 4:46:34 PM
Short term     
Mid term     
Targets 6-month :  0.46 1-year :  0.57
Resists First :  0.39 Second :  0.49
Pivot price 0.35
Supports First :  0.23 Second :  0.19
MAs MA(5) :  0.34 MA(20) :  0.34
MA(100) :  0.36 MA(250) :  1.4
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  20.5 D(3) :  34.3
RSI RSI(14): 50.7
52-week High :  4.67 Low :  0.21
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ PRPH ] has closed above bottom band by 37.5%. Bollinger Bands are 75% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.5 - 0.5 0.5 - 0.5
Low: 0.34 - 0.34 0.34 - 0.34
Close: 0.35 - 0.35 0.35 - 0.35
Company Description

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Headline News

Tue, 17 Jun 2025
ProPhase Labs Announces Successful BE-Smart Test for Detecting Esophageal Cancer; Shares Rise Pre-Bell - marketscreener.com

Tue, 17 Jun 2025
ProPhase Labs (PRPH) Advances with Positive Validation of BE-Smart Test | PRPH Stock News - GuruFocus

Tue, 17 Jun 2025
ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer | PRPH Stock News - GuruFocus

Tue, 17 Jun 2025
ProPhase Labs Announces Successful Study Demonstrating - GlobeNewswire

Tue, 17 Jun 2025
Breakthrough: ProPhase's New Cancer Test Shows 95% Success Rate, Targets $10B Market - Stock Titan

Wed, 11 Jun 2025
ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2025 Earnings Call Transcript - MSN

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 42 (M)
Shares Float 38 (M)
Held by Insiders 7.9 (%)
Held by Institutions 12.1 (%)
Shares Short 231 (K)
Shares Short P.Month 1,280 (K)
Stock Financials
EPS -2.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.36
Profit Margin 0 %
Operating Margin -256 %
Return on Assets (ttm) -31 %
Return on Equity (ttm) -162.4 %
Qtrly Rev. Growth -39.3 %
Gross Profit (p.s.) 0.01
Sales Per Share 0.14
EBITDA (p.s.) -0.69
Qtrly Earnings Growth 0 %
Operating Cash Flow -16 (M)
Levered Free Cash Flow 6 (M)
Stock Valuations
PE Ratio -0.16
PEG Ratio 0
Price to Book value 0.97
Price to Sales 2.48
Price to Cash Flow -0.93
Stock Dividends
Dividend 0.3
Forward Dividend 0
Dividend Yield 85.7%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android